Research records indexed for Elamipretide
This page carries 12 of the 215 records that the literature query returned for Elamipretide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 203 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Elamipretide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential pmid:39940712 | 2025 | review-article, Review | other | Not stated | Indexed as review-article, review. study model from MeSH "Animals" with no rodent species heading. subject headings: Mitochondria; Cardiolipins; Oligopeptides; Oxidative Stress. |
| Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects pmid:40294492 | 2025 | research-article, Review | other | Not stated | Indexed as research-article, review. study model from MeSH "Animals" with no rodent species heading. subject headings: Mitochondria; Cardiolipins; Oligopeptides; Energy Metabolism; Mitochondrial Membranes. |
| The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age pmid:40080911 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Muscle, Skeletal; Myocardium; Heart; Mitochondria; Mice, Inbred C57BL. |
| Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening pmid:40169521 | 2025 | Research Support, Non-U.S. Gov't, research-article | rodent | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Brain; Mitochondria; Mice, Inbred C57BL; Cerebral Hemorrhage; Disease Models, Animal. |
| Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR diagnosis and antioxidant therapy in acute kidney injury pmid:37981044 | 2024 | Research Support, Non-U.S. Gov't | other | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Kidney; Indocyanine Green; Oligopeptides; Antioxidants; Nanoparticles. |
| Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER pmid:38602181 | 2024 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Fatigue; Cardiolipins; Oligopeptides; Muscle Strength; Barth Syndrome. |
| Mitochondrial antioxidant elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice pmid:38688894 | 2024 | Research Support, Non-U.S. Gov't, research-article | rodent | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Hippocampus; Mitochondria; Mice, Inbred C57BL; Memory Disorders; Sleep Deprivation. |
| Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial pmid:39574155 | 2024 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Mitochondrial Myopathies; Oligopeptides; DNA, Mitochondrial; Genotype. |
| Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial pmid:37268435 | 2023 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Mitochondrial Myopathies; Fatigue; Oligopeptides; Merozoite Surface Protein 1; Quality Of Life. |
| The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT) pmid:37462785 | 2023 | Research Support, Non-U.S. Gov't, research-article | other | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from assigned MeSH headings do not state a study model. subject headings: Mitochondria; Peptides; Oligopeptides; Adenosine Diphosphate; Adenosine Triphosphate. |
| Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization pmid:36609266 | 2023 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice". subject headings: Spinal Cord; Lysosomes; Spinal Cord Injuries; Oligopeptides; Phospholipases A2, Cytosolic. |
| Elamipretide reduces pyroptosis and improves functional recovery after spinal cord injury pmid:37081763 | 2023 | Research Support, Non-U.S. Gov't, research-article | other | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Spinal Cord; Spinal Cord Injuries; Oligopeptides; Cytokines; Inflammasomes. |
Where this page sits
Compound page: Elamipretide. Class: Mitochondrial and longevity-associated peptides.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 11764719, Elamipretide. PubChem, National Library of Medicine (2026). pubchem:11764719
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA215244. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ss-31
- Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences of the United States of America (2020). pmid:32554501
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology : JASN (2013). pmid:23813215
- Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation. Heart failure (2017). pmid:29217757
- Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circulation. Heart failure (2016). pmid:26839394
- Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice. Aging cell (2018). pmid:29405550
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Journal of neuroinflammation (2019). pmid:31747905
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.